Table 3:

Effects of CSF biomarkers and APOE on brain morphometry*

	Tau		Aβ42		APOE
	F		R		F
	S1	S2	S1	S2	S1	S2
Hippocampus	5.90^†^‡	7.86^†	.30	.51^†^‡	0.04	3.19
A: Middle temporal LH	5.57^†	0.00	.20	.11	1.24	0.16
B: Inferior parietal LH	1.50	16.67^†^‡	−.04	.11	0.87	2.60
C: Entorhinal LH	2.32	7.35^†	.05	.57^†^‡	0.42	4.39^†
D: Precuneus (toward isthmus) LH	1.42	1.06	−.16	.51^†^‡	0.98	2.99
E: Superior frontal LH	3.41	1.72	−.08	.24	0.06	1.93
A: Middle temporal RH	1.06	0.77	−.19	.27	0.08	1.47
B: Inferior parietal RH	2.24	10.30^†^‡	−.11	.29	0.76	0.90
C: Entorhinal RH	1.35	11.32^†^‡	−.19	.23	0.27	3.62^†
D: Precuneus (toward isthmus) RH	0.50	3.80	−.25	.59^†^‡	1.15	3.85^†
E: Superior frontal RH	0.00	0.31	−.06	.11	0.51	1.24

Note:—S1 indicates Sample 1; S2, Sample 2; LH, left hemisphere; RH, right hemisphere; Aβ42, amyloid beta 42 peptide; APOE, apolipoprotein E; F, F-ratio; R, Pearson r.
* The effects of the APOE genotype and pathologic values of CSF biomarkers tau and Aβ42 on the morphometry (thickness or volume) of the brain in regions that are significantly different between healthy controls and patients with MCI. Because only 3 participants had pathologic Aβ42 values in each sample, the absolute Aβ42 values were used instead of cutoff values, and the relationships were tested with Pearson correlations. In the rest of the analyses, ANOVA was used. Hippocampus is the sum of the left and right hippocampus, regressed on intracranial volume, and the residuals are used in the analyses. The capital letters refer to the cortical ROI from Fig 3.
† P < .05.
‡ P < .05 when the effect of age is controlled for.